Cell therapy developer Artiva refiles for a $100M IPO

seekingalpha06-29

Cell therapy developer Artiva Biotherapeutics (ARTV), whose collaborators include German biotech Affimed (AFMD), has filed with the SEC to raise up to $100M in an initial public offering under the ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2447592619?lang=en_US&edition=fundamental","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1389483753/image_1389483753.jpg","is_english":true,"pubTime":"2024-06-29 22:07","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2447592619","market":"fut","top_or_hot":-1,"title":"Cell therapy developer Artiva refiles for a $100M IPO","media":"seekingalpha","content":"<div>\n<p>Cell therapy developer Artiva Biotherapeutics (ARTV), whose collaborators include German biotech Affimed (AFMD), has filed with the SEC to raise up to $100M in an initial public offering under the ...</p>\n\n<a href=\"https://seekingalpha.com/news/4120802-cell-therapy-developer-artiva-refiles-100m-ipo\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cell therapy developer Artiva refiles for a $100M IPO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCell therapy developer Artiva refiles for a $100M IPO\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-06-29 22:07 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4120802-cell-therapy-developer-artiva-refiles-100m-ipo><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Cell therapy developer Artiva Biotherapeutics (ARTV), whose collaborators include German biotech Affimed (AFMD), has filed with the SEC to raise up to $100M in an initial public offering under the ...</p>\n\n<a href=\"https://seekingalpha.com/news/4120802-cell-therapy-developer-artiva-refiles-100m-ipo\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://seekingalpha.com/news/4120802-cell-therapy-developer-artiva-refiles-100m-ipo","article_id":"2447592619","we_media_id":null,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1389483753/image_1389483753.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2447592619","pubTimestamp":1719670051,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"Cell therapy developer Artiva Biotherapeutics , whose collaborators include German biotech Affimed , has filed with the SEC to raise up to $100M in an initial public offering under the ticker symbol \"ARTV.\" The San Diego, California-based biotech previously filed for a $100M IPO in 2021 to list under the ticker symbol \"RTVA\" and withdrew its plans in late 2022.  Artiva  instead signed an agreement with Affimed  to collaborate on a drug combo involving its lead asset, AlloNK, an NK cell therapy previously known as AB-101. Artiva , a cancer drug developer focused on developing \"off-the-shelf\" product candidates derived from donor cells , is currently testing AlloNK in a Phase 1/1b trial for lupus nephritis, which is set to generate data in H1 2025.","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","AFMD":"Affimed NV"},"translate_title":"细胞疗法开发商Artiva重新申请1亿美元IPO","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AFMD":1},"content_text":"Cell therapy developer Artiva Biotherapeutics (ARTV), whose collaborators include German biotech Affimed (AFMD), has filed with the SEC to raise up to $100M in an initial public offering under the ticker symbol \"ARTV.\" The San Diego, California-based biotech previously filed for a $100M IPO in 2021 to list under the ticker symbol \"RTVA\" and withdrew its plans in late 2022.  Artiva (RTVA) instead signed an agreement with Affimed (AFMD) to collaborate on a drug combo involving its lead asset, AlloNK, an NK cell therapy previously known as AB-101. Artiva (ARTV), a cancer drug developer focused on developing \"off-the-shelf\" product candidates derived from donor cells (allogeneic), is currently testing AlloNK in a Phase 1/1b trial for lupus nephritis, which is set to generate data in H1 2025.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.27.0","shortVersion":"4.27.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2447592619"}